RT Journal Article SR Electronic T1 Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1793 OP 1796 DO 10.2967/jnumed.117.192450 VO 58 IS 11 A1 Jeremie Calais A1 Johannes Czernin A1 Matthias Eiber A1 Wolfgang P. Fendler A1 Jeannine Gartmann A1 Anthony P. Heaney A1 Andrew E. Hendifar A1 Joseph R. Pisegna A1 J. Randolph Hecht A1 Edward M. Wolin A1 Roger Slavik A1 Pawan Gupta A1 Andrew Quon A1 Christiaan Schiepers A1 Martin S. Allen-Auerbach A1 Ken Herrmann YR 2017 UL http://jnm.snmjournals.org/content/58/11/1793.abstract AB In this prospective referring-physician–based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.